{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055255","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.364148+00:00","generated_at":"2026-06-28T11:15:26.157506+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Pharma Q3 net loss narrows to $0.09/shr; NUPLAZID sales up 9% to $131.6M","bullets":["Net loss per share of $0.09, improved from $0.54 loss in Q3 2020; revenue $131.6M (+9% YoY).","2021 NUPLAZID sales guidance narrowed to $480M-$500M from $480M-$515M; R&D guidance lowered.","FDA meeting scheduled to discuss pimavanserin sNDA resubmission for dementia-related psychosis subgroups.","Top-line results expected Q4 2021 for trofinetide (Rett syndrome) and Q1 2022 for ACP-044 (pain).","Promoted Brendan Teehan to EVP, COO, Head of Commercial; Julie Fisher to SVP, Marketing."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055255","json":"https://secwatch.observer/filing/0001564590-21-055255.json","markdown":"https://secwatch.observer/filing/0001564590-21-055255.md","text":"https://secwatch.observer/filing/0001564590-21-055255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000156459021055255/0001564590-21-055255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000156459021055255/acad-8k_20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:15:26.157506+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}